The FDA reviewed DHEA in exactly one form: Intrarosa, a 6.5 mg vaginal insert dosed once daily for postmenopausal dyspareunia. That clearance does not speak to the patient sitting in front of an endocrinologist with Addison's disease, the woman whose serum DHEA-S has been in the bottom decile for her age since her forties, or the IVF poor responder whose reproductive endocrinologist wants 75 mg a day for ten weeks. It also does not speak to the more pedestrian reality that women generally need 10 to 25 mg a day for replacement and men 25 to 50 mg, while the off-the-shelf supplement market starts at 25 mg and climbs to 100 mg. Baseline DHEA-S, sex, age, free testosterone, SHBG, and tolerance for androgenization (acne, oily skin, hair thinning) all move the right dose around.
Compounding lets the prescriber pick the dose, not the supplement aisle. A 10 mg or 15 mg capsule for a woman whose DHEA-S is creeping toward the young-adult reference range without overshooting it. A sublingual troche when oral first-pass sulfation is producing more DHEA-S than free DHEA than the prescriber wants. A topical cream for a patient who cannot tolerate oral dosing. Identity, potency, and excipient profile are verified to USP <795> standards, which addresses the documented variability in OTC supplement content (the Parasrampuria 1998 JAMA paper that found commercial DHEA capsules often missed their labeled dose by wide margins). For postmenopausal dyspareunia specifically, Intrarosa is the right first call; compounded vaginal DHEA exists for documented patient-specific reasons like excipient sensitivity, not as a substitute.
This is what pharmacy looked like before mass manufacturing arrived. A prescriber wrote the order, a pharmacist prepared it, and the bottle had one patient's name on it. Compounded DHEA is that older arrangement, kept honest by modern oversight.
In brief
DHEA Explained
DHEA (dehydroepiandrosterone) is a steroid hormone your adrenal glands make in large amounts during early adulthood 1. It peaks around age 20, 25 and then declines roughly 2% per year, so an 80-year-old has about 10, 20% of the DHEA they had at 25. The body uses it as a starting material to make small amounts of testosterone and estrogen inside specific tissues, a process called intracrinology 3.
Only one FDA-approved DHEA product exists: Intrarosa, a vaginal insert (prasterone 6.5 mg) approved in 2016 for painful intercourse in postmenopausal women caused by vaginal tissue changes 51. Oral DHEA, by contrast, is sold over-the-counter as a dietary supplement, unusual for a hormone precursor 9. Studies have shown OTC products often don't contain the dose stated on the label.
RonanRx compounds DHEA when the OTC supplement market or Intrarosa cannot meet a documented clinical need, for example, very low doses (10, 25 mg) that aren't commercially available, sublingual or topical forms, or formulations made to USP pharmacy standards for identity and purity. The evidence for systemic DHEA is mixed: it helps women with adrenal insufficiency (Addison's disease), is being studied in IVF poor responders, and has shown only modest or null effects in healthy older adults for cognition, mood, or body composition 1026.
At a glance
Quick Facts About DHEA
Category
Adrenal androgen precursor (C19 steroid); intracrine substrate for tissue-specific conversion to testosterone and estradiol
Active ingredient
Dehydroepiandrosterone (DHEA), also known as prasterone, bioidentical to the endogenous adrenal-derived hormone; circulates predominantly as the sulfate ester DHEA-S
FDA-approved branded product
Intrarosa (prasterone 6.5 mg vaginal insert), approved November 2016 for moderate-to-severe dyspareunia in postmenopausal women with vulvovaginal atrophy / genitourinary syndrome of menopause
OTC status
Oral DHEA is sold OTC in the US as a dietary supplement under DSHEA 1994, unusual for a sex-steroid prohormone. Commercial supplement DHEA content has been shown to vary substantially from labeled potency [parasrampuria1998]. Compounded DHEA under 503A addresses dose, route, and quality needs that the OTC supplement market does not meet.
FDA-approved for intravaginal prasterone in postmenopausal dyspareunia (Labrie, Archer phase III). Systemic oral DHEA evidence is mixed: positive in adrenal insufficiency replacement (Arlt 1999, Hunt 2000, Gurnell 2008, Alkatib 2009 meta-analysis); null or modest for aging, cognition, and body composition in eugonadal elderly (Nair 2006 NEJM, Percheron 2003); controversial in IVF poor responders (Wiser 2010, Cochrane Nagels 2015).
Compounded under
503A, patient-specific prescription only, where the OTC supplement or FDA-approved Intrarosa product does not meet documented clinical need (dose, route, excipient sensitivity, or USP-grade purity)
Important compounding context
Because oral DHEA is available OTC as a dietary supplement, compounded oral DHEA is held to the FDA 503A 'essentially-a-copy' threshold even though there is no FDA-approved oral DHEA product to compare against. RonanRx compounds DHEA when the prescriber documents that OTC supplements cannot meet the patient's clinical need, typically for sub-OTC-strength dosing in women (10, 25 mg), sublingual or topical formulation, or USP <795>-compliant identity and purity assurance.
Doping status
Prohibited in-competition and out-of-competition by the World Anti-Doping Agency (WADA) as an anabolic androgenic steroid
Prescription review
Patient-Specific Prescription Only
DHEA on this page is a 503A compounded preparation. Every dose is made on a prescription, for a named patient, by a licensed pharmacist. It is not a stocked, mass-manufactured product.
Made to order, not off a shelf. No batch sits in a warehouse waiting for buyers. Your prescription is what triggers the prep.
Named-patient label. The bottle carries your name. The batch records carry your prescription.
Dose, strength, and route chosen for you. A prescriber who knows your chart decides what gets compounded, not a manufacturer who set the strength for a trial population.
Licensed pharmacist on the hook. A real person, with a license that can be pulled, signs off on every prep. State inspectors check the facility.
Compounded drugs are not FDA-approved. They should not be evaluated using branded-drug trial data. Availability varies by state and prescribed medication.
A research-use-only website ships a vial from a warehouse. There is no prescription, no pharmacist, no facility inspection, and no way to recall the product if something is wrong with it. If the vial is mislabeled, contaminated, or under-potent, there is nobody whose license is at stake.
A 503A compounding pharmacy is the other thing. Your doctor writes the prescription. A licensed pharmacist, whose name is on the label, prepares the medicine in a facility the state inspects. If something goes wrong, there is a person and a license on the hook, and a documented chain of custody on every lot. That accountability is what makes it safe.
What it is
What is DHEA?
Dehydroepiandrosterone (DHEA; 3β-hydroxy-5-androsten-17-one), also known by the international nonproprietary name prasterone, is a 19-carbon (C19) steroid synthesized predominantly in the zona reticularis of the adrenal cortex. In circulation it exists in two interconverting forms: free DHEA and the sulfate ester DHEA-S. DHEA-S is the most abundant steroid in human blood, quantitatively orders of magnitude higher than testosterone, and serves as a long-half-life reservoir from which tissues regenerate free DHEA for local conversion to active sex steroids 34.
DHEA was first isolated and characterized in 1934. Its physiological role as the substrate for adrenarche, the prepubertal rise in adrenal androgens around age 6, 8, was clarified across the 1980s and 1990s 6. Serum DHEA-S follows a distinctive lifespan trajectory: low in childhood, rising at adrenarche, peaking in the third decade, then declining approximately 1, 2% per year, a pattern sometimes called 'adrenopause' 12.
In the United States, oral DHEA is sold over-the-counter as a dietary supplement under the Dietary Supplement Health and Education Act of 1994, a regulatory anomaly for a sex-steroid prohormone. The only FDA-approved DHEA prescription product is Intrarosa, a 6.5 mg prasterone vaginal insert approved in November 2016 for moderate-to-severe dyspareunia in postmenopausal women 51.
How it works
How DHEA Works
Class
Adrenal androgen precursor
First studied
1934 (isolation)
Common forms
Oral capsule
Compounding category
503A, patient-specific prescription
DHEA is best understood not as a hormone with direct receptor agonism but as an intracrine substrate. Labrie's 1991 'intracrinology' framework 3 described how peripheral tissues, vagina, skin, bone, brain, adipose, express the steroidogenic enzymes (steroid sulfatase, 3β-HSD, 17β-HSD, aromatase, 5α-reductase) to convert circulating DHEA and DHEA-S locally into testosterone, dihydrotestosterone, or estradiol, producing tissue-specific androgen and estrogen action without raising serum levels of those active hormones.
After adrenarche, DHEA-S accounts for the bulk of adrenal androgen output. In postmenopausal women, with ovarian estrogen and androgen synthesis having ceased, essentially all sex-steroid action in peripheral tissues derives from intracrine conversion of circulating DHEA and DHEA-S 350. This is the mechanistic basis for intravaginal prasterone (Intrarosa): locally delivered DHEA is converted by vaginal epithelial enzymes to estradiol and testosterone, restoring vaginal trophic effects while serum sex-steroid levels remain in the postmenopausal range 384743.
DHEA also has direct, AR/ER-independent actions at low affinity on neurosteroid receptors including GABA-A (negative allosteric modulator) and NMDA, and binds the σ-1 receptor, pharmacologically positioning DHEA as a neurosteroid distinct from its role as an androgen/estrogen precursor 14. The clinical relevance of these neurosteroid actions for mood, cognition, and well-being remains an active research question with mixed clinical results.
Research history
DHEA Research History
DHEA was isolated in 1934 by Butenandt from male urine and chemically characterized over the following decade. Its physiology as an adrenal C19 steroid was established by the 1950s, but its function, beyond being a precursor, remained obscure for decades. The age-related decline of DHEA-S was first quantified at scale by Orentreich and colleagues in cross-sectional 1 and longitudinal 2 studies in J Clin Endocrinol Metab, establishing the trajectory now called adrenopause.
Labrie's 1991 'intracrinology' paper in Mol Cell Endocrinol 3 reframed DHEA as a substrate for tissue-specific local sex-steroid synthesis rather than a hormone with direct receptor agonism. This framework became the mechanistic basis for both the systemic and the local (intravaginal) DHEA literature. The first randomized replacement trial in eugonadal aging adults was Morales 1994 7, 50 mg/day oral DHEA for 3 months in men and women aged 40, 70 produced rises in DHEA-S to young-adult levels and improved subjective well-being, but the study was small (n=30) and end points were patient-reported.
The clearest clinical use case emerged in adrenal-insufficiency replacement. Arlt and Allolio's 1999 NEJM trial 10 randomized 24 women with adrenal insufficiency to 50 mg/day DHEA versus placebo for 4 months and reported improvements in mood, fatigue, sexuality, and well-being scores, the first rigorous demonstration of a DHEA-replacement indication. Hunt 2000 11 in JCEM reproduced the mood and fatigue findings in 39 Addison's patients. The DHEAge study by Baulieu and colleagues 151415 tested 50 mg/day for 1 year in 280 older adults and reported skin and libido improvements in women over age 70 but no benefit on muscle function. Nair 2006 NEJM 26, the definitive Mayo Clinic trial in 87 elderly men and 57 elderly women, reported no benefit of DHEA (or low-dose testosterone in men) on body composition, physical performance, insulin sensitivity, or quality of life at 2 years.
Bone and body-composition evidence accumulated through the 2000s. Villareal 2004 JAMA 19 showed reduced abdominal visceral fat and improved insulin sensitivity at 6 months in older adults on 50 mg/day. Jankowski's 2006 and 2008 JCEM papers 2425 demonstrated bone-mineral-density gains in older adults with DHEA replacement, mediated by aromatization to estrogens. Weiss 2009 31 extended the bone findings to 2 years. Gurnell 2008 28 in JCEM reported the longest randomized DHEA trial, 12 months in primary adrenal insufficiency, with sustained subjective benefit. The Alkatib 2009 meta-analysis 29 in JCEM integrated 10 randomized trials in adrenal insufficiency and concluded that DHEA produced a small but statistically significant improvement in health-related quality of life. The Endocrine Society's 2016 clinical practice guideline on primary adrenal insufficiency (Bornstein) 45 acknowledges this evidence but stops short of routinely recommending DHEA replacement, citing variable response.
Female sexual function and menopause symptoms have produced mixed results for systemic DHEA. The Genazzani 2003, 2011 3635 studies reported endocrine and climacteric-symptom effects of low-dose oral DHEA in postmenopausal women. Panjari 2009 J Sex Med 30 randomized 93 postmenopausal women with low libido to 50 mg/day oral DHEA versus placebo for 6 months and found no significant improvement in the primary sexual-function endpoint. The 2015 Cochrane review (Scheffers) 41 of 28 trials concluded that there is no clinically significant effect of DHEA on most menopausal symptoms; the women's androgen-therapy Endocrine Society guideline 4040 does not recommend systemic DHEA for sexual dysfunction outside of adrenal insufficiency. Davis 2011 JCEM 34 provides a contemporary clinical review of DHEA replacement in postmenopausal women.
The intravaginal prasterone program, Labrie's principal late-career work, generated the only successful FDA-approval pathway. Labrie 2011 Climacteric 33 was the first published phase III demonstration of intravaginal DHEA for dyspareunia. Subsequent phase III evidence including Archer 2015 Menopause 42 confirmed efficacy on pain at sexual activity and vaginal trophic endpoints without clinically meaningful elevation of serum estrogens or androgens 384347. FDA approval of Intrarosa followed in November 2016 51. Labrie's 2017 combined analysis in Menopause 46 integrated the program's evidence base.
IVF poor-responder protocols using DHEA were pioneered by Gleicher and Barad at the Center for Human Reproduction. The Wiser 2010 randomized trial 32 in 33 poor responders reported improved live birth rates with 75 mg/day DHEA pre-stimulation. Yeung 2014 39 was a larger pilot RCT (n=72) that showed no significant benefit on the primary ovarian-response endpoint. The Cochrane review 4444 of androgens including DHEA in poor responders concluded that 'androgen pre-treatment may improve live birth rate' but evidence is low quality. The Zhang 2020 Hum Reprod Update network meta-analysis 48 integrated this evidence into broader poor-responder treatment strategies. DHEA for IVF remains broadly adopted in reproductive endocrinology practice despite the uncertain Cochrane verdict, a tension that should be communicated honestly to patients.
Lupus (SLE) and other autoimmune indications. Prasterone (Genelabs' GL-701) was tested in multiple phase III SLE trials, with Petri 2002 16 (steroid-sparing) and Petri 2004 17 (disease activity) showing modest signals on lupus activity in subgroups. The FDA did not ultimately approve prasterone for SLE; the development program closed without an approved indication. The mechanism rationale rests on the consistently low DHEA-S levels in patients with active SLE 18.
Pharmacokinetics and oral-route characterization spans Arlt 1998 8, Legrain 2000 13, and Acacio 2004 23. Quality-control studies of the commercial OTC DHEA supplement market, Parasrampuria 1998 in JAMA 9, found that several over-the-counter products contained DHEA at concentrations substantially different from the labeled potency. The 503A compounding pathway, governed by USP <795> for nonsterile preparations 54, addresses these identity and potency concerns when supplements cannot meet documented clinical need.
Timeline
DHEA Timeline
1934Butenandt isolates DHEA from male urine
1984Orentreich et al 1. (JCEM) characterize age changes and sex differences in serum DHEA-S concentrations across adulthood, establishes the adrenopause trajectory
1991Labrie publishes 'Intracrinology' in Mol Cell Endocrinol, reframes DHEA as substrate for tissue-specific local sex-steroid synthesis 3
1992Orentreich's longitudinal DHEA-S study (JCEM) confirms the within-subject decline over time, distinct from cohort effects 2
1994DSHEA enacted in the US, oral DHEA classified as a dietary supplement and sold OTC
1994Morales et al 7. (JCEM), first randomized DHEA replacement trial in advancing-age men and women, small (n=30), positive on subjective well-being
1998Arlt et al 8. (JCEM) characterize oral DHEA pharmacokinetics and peripheral conversion to androgens and estrogens
1998Parasrampuria et al 9. (JAMA) document substantial variability in DHEA content of commercial OTC supplement products
1999Arlt et al 10. (NEJM), DHEA replacement in women with adrenal insufficiency improves mood, fatigue, sexuality, and well-being scores in a 4-month placebo-controlled crossover trial
2000Hunt et al 11. (JCEM) reproduce mood and fatigue findings in 39 patients with Addison's disease on DHEA replacement
2000Legrain et al 13. (JCEM), pharmacokinetic and pharmacodynamic study of DHEA in healthy elderly subjects
2000Baulieu et al 14. (PNAS) publish DHEAge study results, sociobiomedical synthesis of DHEA aging trial in 280 older adults
2002Petri et al 16. (Arthritis Rheum) report prasterone steroid-sparing effects in women with SLE
2003Percheron et al 15. (Arch Intern Med), DHEAge 1-year follow-up shows no effect on muscle function or cross-sectional area in older adults
2004Villareal & Holloszy (JAMA), DHEA reduces abdominal visceral fat and improves insulin action in elderly women and men over 6 months 19
2004Acacio et al 23. (Fertil Steril), long-term daily oral DHEA pharmacokinetics in healthy young men
2004Petri et al 17. (Arthritis Rheum), prasterone effects on SLE disease activity and symptoms in a second phase 3 trial
2005Dhatariya et al 20. (Diabetes), DHEA replacement improves insulin sensitivity and lipids in hypoadrenal women
2006Nair et al 26. (NEJM), definitive Mayo Clinic 2-year RCT in 87 men and 57 women aged 60+: no benefit of DHEA on body composition, performance, insulin sensitivity, or quality of life
2006Jankowski et al 24. (JCEM), DHEA replacement improves bone mineral density in older adults
2008Gurnell et al 28. (JCEM), long-term (12-month) DHEA replacement RCT in primary adrenal insufficiency, sustained subjective benefit
2008Jankowski et al 25. (JCEM), DHEA-driven BMD increases mediated by aromatization to estrogens
2009Alkatib et al 29. (JCEM), systematic review and meta-analysis of 10 RCTs concludes DHEA produces a small but statistically significant improvement in health-related quality of life in adrenal insufficiency
2009Panjari et al 30. (J Sex Med), RCT of 50 mg/day oral DHEA in postmenopausal women with low libido: no significant effect on primary sexual-function endpoint
2009Weiss et al 31. (Am J Clin Nutr), 1- and 2-year effects of DHEA on bone in older adults
2010Wiser et al 32. (Hum Reprod), randomized prospective trial: addition of DHEA to poor-responder IVF improves pregnancy rate
2011Labrie et al 33. (Climacteric), first phase III RCT of intravaginal prasterone for dyspareunia
2011Davis (JCEM) clinical review, DHEA replacement for postmenopausal women 34
2013Labrie et al 38. (J Steroid Biochem Mol Biol), intravaginal prasterone provides local action without clinically significant change in serum estrogens or androgens
2013Corona et al 37. (JCEM), meta-analysis of placebo-controlled trials of DHEA in elderly men: only small effects
2014Yeung et al 39. (Fertil Steril), randomized controlled pilot trial of DHEA in poor responders: no significant effect on primary ovarian-response endpoint
2014Wierman et al 40. (JCEM), Endocrine Society guideline on androgen therapy in women, does not recommend systemic DHEA outside of adrenal insufficiency
2015Scheffers et al 41. (Cochrane), systematic review of 28 RCTs concludes no clinically significant effect of systemic DHEA on most menopausal symptoms
2015Nagels et al 44. (Cochrane), androgens (DHEA or testosterone) for women undergoing assisted reproduction: low-quality evidence of possible live-birth-rate improvement
2015Archer et al 42. (Menopause), phase III RCT of intravaginal prasterone for pain at sexual activity (dyspareunia)
2015Ke et al 43. (J Steroid Biochem Mol Biol), serum sex steroid measurements after 12 weeks of intravaginal 0.50% DHEA: levels remain in postmenopausal range
2016Bornstein et al 45. (JCEM), Endocrine Society guideline on primary adrenal insufficiency acknowledges DHEA evidence but does not routinely recommend
2016FDA approves Intrarosa (prasterone 6.5 mg vaginal insert) for moderate-to-severe dyspareunia in postmenopausal women with vulvovaginal atrophy (November 17, 2016) 51
2017Labrie et al 46. (Menopause), combined data of intravaginal prasterone against vulvovaginal atrophy of menopause
2017Labrie & Martel (Horm Mol Biol Clin Investig), confirm strictly local action of low-dose (6.5 mg) intravaginal DHEA 47
2020Zhang et al 48. (Hum Reprod Update), network meta-analysis of adjuvant treatment strategies for poor responders in IVF, including DHEA
Natural role
Biological Role of DHEA
DHEA-S is, by mass, the most abundant steroid hormone in the human circulation in young adults. Its biological role is to serve as a circulating reservoir for tissue-level intracrine generation of androgens and estrogens 3. This intracrine system is the principal source of sex-steroid action in postmenopausal women and contributes substantially to total androgen exposure in adult men beyond what is provided by testicular testosterone.
Adrenarche, the prepubertal rise in adrenal androgens around ages 6, 8, precedes gonadal puberty by several years and produces the first appearance of pubic and axillary hair, mild acne, and adult-type body odor. The molecular trigger for adrenarche remains incompletely understood but involves remodeling of the adrenal cortex with expansion of the zona reticularis and a shift in CYP17A1 catalytic activity toward 17,20-lyase function 65.
Adrenopause, the age-related decline of DHEA and DHEA-S, was documented by Orentreich and colleagues across cross-sectional 1 and longitudinal 2 studies in the 1980s and early 1990s. The decline is roughly linear at 1, 2% per year from the peak in the third decade. Whether replacing DHEA in aging adults provides clinical benefit beyond restoring laboratory values has been the subject of three decades of trials with largely modest or null results in eugonadal aging populations 261537.
Clinical contexts studied
Clinical Contexts for DHEA
Moderate-to-severe dyspareunia in postmenopausal women with vulvovaginal atrophy fda approved
FDA-approved indication for manufactured Intrarosa.
Intrarosa (prasterone 6.5 mg vaginal insert) is FDA-approved (November 2016) for moderate-to-severe dyspareunia, a symptom of vulvovaginal atrophy due to menopause 51. Pivotal phase III evidence by Labrie 2011 33 and Archer 2015 42 demonstrated improvement in vaginal pH, percentage of parabasal and superficial cells, and most bothersome symptom (pain at sexual activity) compared with placebo over 12 weeks. PK and serum endocrine data 384347 confirm that local action is achieved without clinically significant elevation of serum estradiol, testosterone, or DHEA-S beyond postmenopausal reference ranges. The combined-data analysis 46 integrates the program evidence.
Branded product: Intrarosa (prasterone vaginal insert, originally Endoceutics, marketed by Millicent Pharma)
Adrenal-androgen replacement in primary or secondary adrenal insufficiency emerging
Off-label; supported by multiple randomized trials and a meta-analysis but not routinely recommended by the Endocrine Society 2016 guideline.
The Arlt 1999 NEJM trial 10 in 24 women with adrenal insufficiency randomized to 50 mg/day oral DHEA versus placebo for 4 months reported improvements in mood, fatigue, sexuality, and overall well-being. Hunt 2000 11 reproduced these findings in 39 Addison's patients. The Callies 2001 follow-on 12 examined body composition, leptin, bone turnover, and exercise capacity. Gurnell 2008 28 extended the evidence to 12 months. The Alkatib 2009 meta-analysis 29 of 10 RCTs concluded that DHEA in adrenal insufficiency produces a small but statistically significant improvement in health-related quality of life. Dhatariya 2005 20 reported insulin-sensitivity and lipid effects in hypoadrenal women. The Endocrine Society 2016 guideline 45 notes that DHEA replacement may be considered in adrenally-insufficient women with low libido or persistent symptoms despite optimal glucocorticoid and mineralocorticoid replacement, but stops short of routine recommendation. Brooke 2006 27 reported reduction in GH dose requirement in hypopituitary women on DHEA replacement.
Off-label; widely adopted in fertility practice but supporting evidence is low quality per Cochrane.
DHEA pre-stimulation in women with diminished ovarian reserve was popularized by Gleicher and Barad at the Center for Human Reproduction in the 2000s. Wiser 2010 32 was a randomized prospective trial in 33 poor responders showing improved pregnancy rates with 75 mg/day DHEA pre-stimulation. Yeung 2014 39 was a larger pilot (n=72) that showed no significant effect on the primary ovarian-response endpoint. The Cochrane 2015 review by Nagels 44 concluded that androgen pre-treatment 'may improve live birth rate' but evidence is low quality. The Zhang 2020 Hum Reprod Update network meta-analysis 48 integrated this evidence across poor-responder strategies. DHEA for IVF remains broadly adopted in reproductive endocrinology practice despite the uncertain Cochrane verdict, patients should be counseled that benefit is plausible but unproven.
Off-label; phase III evidence (prasterone, Genelabs) showed modest signals but FDA approval was not granted; further development was discontinued.
Patients with active SLE have consistently low circulating DHEA-S 18. Petri 2002 16 reported steroid-sparing effects of prasterone in women with SLE; Petri 2004 17 examined effects on disease activity and symptoms. The Genelabs prasterone development program (GL-701) did not produce an FDA-approved SLE indication. Use for SLE remains investigational with modest published evidence.
Off-label; supported by randomized trials with effect sizes that are statistically significant but smaller than those of bisphosphonates or estrogen replacement.
Jankowski 2006 24 and 2008 25 reported significant gains in lumbar spine and hip BMD with 12-month oral DHEA 50 mg/day in older adults, with mediation by aromatization to estrogens. Weiss 2009 31 extended findings to 2 years. The Nair 2006 NEJM trial 26 did not find body-composition or strength benefit at 2 years but did not power for BMD. The Endocrine Society women's androgen guideline 40 does not recommend systemic DHEA for osteoporosis prevention; FDA-approved bone-density agents remain first-line.
Postmenopausal sexual function and well-being emerging
Off-label; systematic-review evidence does not support routine systemic DHEA for menopausal symptoms.
The Panjari 2009 J Sex Med trial 30 randomized 93 postmenopausal women with low libido to oral DHEA 50 mg/day versus placebo for 6 months and found no significant effect on the primary sexual-function endpoint. The 2015 Cochrane review by Scheffers 41 of 28 RCTs concluded that DHEA does not produce a clinically significant effect on most menopausal symptoms. Davis 2011 34 and Genazzani 2011 35 reviewed the field and reported small effects in subgroups; Genazzani 2003 36 examined endocrine and neuroactive steroid effects. The Endocrine Society 2014 women's androgen guideline 40 does not recommend systemic DHEA for sexual dysfunction outside of adrenal insufficiency.
Cognition, mood, and aging in eugonadal elderly emerging
Off-label; randomized evidence in healthy older adults is largely null or modest.
The Nair 2006 NEJM trial 26, 87 men and 57 women aged 60, 88 randomized to DHEA, low-dose testosterone (men), or placebo for 2 years, found no benefit on body composition, physical performance, insulin sensitivity, or quality of life. The DHEAge study 14 reported small skin and libido improvements in women over 70 but no muscle-function benefit. Schmidt 2005 21 reported antidepressant effects of DHEA monotherapy in midlife-onset major and minor depression, one of the few positive mood signals in the systemic-DHEA literature. Wolkowitz 1997 22 reported an earlier signal in major depression. Corona 2013 37, meta-analysis of placebo-controlled trials in elderly men, concluded effects are small and inconsistent 15. The Rabijewski 2020 Polish Menopause Society position statement 49 reviews the European clinical landscape.
Off-label use
Off-Label Uses of DHEA
Adrenal-androgen replacement in primary or secondary adrenal insufficiency emerging
Off-label; consistent randomized evidence and meta-analytic support, but Endocrine Society does not routinely recommend.
Multiple RCTs 101128 and a meta-analysis 29 support DHEA replacement for symptomatic women with adrenal insufficiency who remain symptomatic despite optimal glucocorticoid and mineralocorticoid replacement. The Endocrine Society 2016 guideline 45 permits but does not routinely recommend.
Off-label; broadly adopted in reproductive endocrinology, supporting evidence is low quality per Cochrane.
Empiric pre-stimulation with oral DHEA 25 mg three times daily (or 75 mg/day) for 6, 12 weeks is widely used in poor-responder IVF cycles 48. The Wiser 2010 RCT 32 was positive on pregnancy rate; the Yeung 2014 39 pilot was null on the primary endpoint; the Cochrane 2015 review 44 concluded evidence is low quality.
Off-label; phase III evidence did not lead to FDA approval; development discontinued.
Petri 2002 and 2004 1617 reported modest steroid-sparing and symptom signals; the Genelabs prasterone development program did not produce approval 18. Use is investigational.
FDA-approved use
FDA-Approved Uses of DHEA
Brand
Indication
Year
Route
Intrarosa (prasterone)
Moderate-to-severe dyspareunia, a symptom of vulvovaginal atrophy, due to menopause
2016
Intravaginal insert
Intrarosa is a prasterone (DHEA) 6.5 mg vaginal insert FDA-approved on November 16, 2016, for moderate-to-severe dyspareunia, a symptom of vulvovaginal atrophy, due to menopause 51. Approval was based on phase III evidence by Labrie 2011 33 and Archer 2015 42 demonstrating improvement in the co-primary endpoints (vaginal pH, percentage of parabasal cells, percentage of superficial cells, and most bothersome symptom of pain at sexual activity) compared with placebo over 12 weeks. Serum sex-steroid measurements during treatment 384347 remained within postmenopausal reference ranges, supporting the mechanistic claim of intracrine local action.
Intrarosa is the only FDA-approved DHEA product. Oral DHEA is sold OTC as a dietary supplement and is not FDA-approved for any indication. Compounded oral DHEA, intravaginal DHEA, and topical DHEA preparations are not FDA-approved products.
Compounded use
Compounded DHEA (503A)
Compounded DHEA under 503A is dispensed only when the prescribing clinician documents a patient-specific clinical need that neither the FDA-approved Intrarosa product nor the OTC dietary-supplement market can meet 51. DHEA occupies an unusual regulatory position: oral DHEA is sold OTC as a dietary supplement under DSHEA 1994, while the only FDA-approved DHEA prescription product is intravaginal Intrarosa. This means compounded oral DHEA is approached with the FDA 'essentially-a-copy' framework in mind, even though there is no FDA-approved oral comparator 52.
Documented patient-specific clinical needs typically fall into four categories: (1) sub-OTC dose individualization, particularly for women, where typical OTC capsule strengths (25 mg, 50 mg, 100 mg) exceed the 10, 25 mg doses commonly appropriate for female replacement based on the published trials 101128; (2) sublingual or topical formulation when oral first-pass sulfation must be reduced or when the patient cannot tolerate oral dosing; (3) excipient sensitivity to components of OTC supplements (titanium dioxide, magnesium stearate, common allergens); and (4) USP <795>-compliant identity, potency, and purity assurance, addressing the well-documented variability of commercial OTC DHEA content 95451.
Compounded preparations are not bioequivalent to Intrarosa and are not bioequivalent to any specific OTC product 51. PK characteristics depend on the route, excipient base, and concentration. Sublingual compounded DHEA is hypothesized to bypass first-pass sulfation and produce a different DHEA-to-DHEA-S ratio than oral capsules, published PK data for sublingual DHEA are limited 23813 and individualized monitoring is appropriate.
DHEA is a WADA-prohibited anabolic agent in- and out-of-competition for athletes subject to anti-doping testing 51. Compounded preparations do not exempt the user from sport-specific bans. Patients who are competitive athletes must be informed before dispensing.
RonanRx does not fill DHEA prescriptions that read as routine substitution for an OTC supplement without documented clinical rationale, and is particularly attentive to the 'essentially-a-copy' framing for oral DHEA. Pharmacist review confirms a documented clinical reason that the OTC market or Intrarosa cannot meet the patient's need 51.
Formulations and routes
DHEA Formulations and Routes
Form
Concentration
Description
Compounded oral capsule (micronized DHEA)
Custom, typically 5, 10, 15, 20, 25, or 50 mg per capsule; women's replacement doses commonly 10, 25 mg, men's commonly 25, 50 mg
Nonsterile oral capsule compounded under USP <795> standards on patient-specific prescription. Micronized API supports more reproducible dissolution and absorption than coarser supplement-grade material.54813
Compounded sublingual troche or lozenge
Custom, typically 5, 25 mg
Sublingual delivery is hypothesized to partially bypass first-pass hepatic sulfation, altering the DHEA-to-DHEA-S ratio relative to oral capsules. Published PK data specific to sublingual DHEA are limited.5423
Compounded topical cream or gel
Custom, commonly 5, 10 mg per dose
Topical/transdermal delivery for selected patients with intolerance to oral routes. Systemic exposure depends on excipient base and skin site; pharmacokinetics are not well characterized in the published literature.54
Intrarosa is the only FDA-approved DHEA product, supplied as 6.5 mg prasterone vaginal inserts for once-daily use in postmenopausal dyspareunia.51
OTC oral capsule (dietary supplement, not FDA-approved)
Commonly 25 mg, 50 mg, or 100 mg
Sold OTC under DSHEA 1994. Independent analyses have documented substantial variability between labeled and assayed DHEA content in commercial supplement products [parasrampuria1998]. Not subject to FDA pre-market efficacy or potency review.9
Routes used in published literature: oral, sublingual, topical, transdermal, vaginal.
Dosing
DHEA Dosing
Route
Population
Range
Duration
Study type
Intravaginal
Postmenopausal women with moderate-to-severe dyspareunia from vulvovaginal atrophy (Intrarosa labeled regimen)
6.5 mg prasterone vaginal insert once daily at bedtime
Doctor-prescribed and titrated. Female replacement doses are commonly 10, 25 mg/day, lower than typical OTC capsule strengths and one rationale for compounding. Male replacement (where indicated, typically only in primary adrenal insufficiency) is commonly 25, 50 mg/day 101128. Intravaginal Intrarosa is dosed at 6.5 mg once daily per label and should not be substituted with compounded oral DHEA for the dyspareunia indication 51.
Target DHEA-S to the young-adult sex- and age-specific reference range. In women, free testosterone, total testosterone, SHBG, and estradiol should be monitored periodically, androgenization (acne, oily skin, hirsutism, scalp hair thinning) is the most common dose-limiting effect and prompts dose reduction. Higher doses (>50 mg/day in women) are commonly associated with supraphysiologic testosterone elevations 44.
IVF poor-responder pre-stimulation protocols typically use 75 mg/day for 6, 12 weeks. The Cochrane review notes evidence is low quality; patients should be counseled accordingly. Compounded DHEA mirrors the supplement-derived dose strategy rather than introducing novel regimens 32.
Doses listed are literature context, not patient instructions. Dosing decisions are made by the prescribing doctor and tailored to the individual patient.
Safety
DHEA Safety
Safety overview
The dominant safety concerns with systemic DHEA are dose-dependent androgenic effects, particularly in women: acne, oily skin, hirsutism, scalp hair thinning, and (less commonly) deepening of the voice. These reflect peripheral conversion of DHEA to testosterone and DHT, and they are the most common reason for dose reduction or discontinuation in clinical trials 102630. Acne and oily skin are reported in 10, 30% of women on 50 mg/day in the published trials and resolve with dose reduction.
Estrogenic effects from peripheral aromatization (breast tenderness, vaginal spotting, endometrial stimulation) are uncommon at typical replacement doses but have been reported. Long-term safety data on endometrial effects of systemic DHEA in postmenopausal women are limited; the Endocrine Society 2014 women's androgen-therapy guideline 40 does not recommend long-term systemic DHEA outside of adrenal insufficiency in part because of these uncertainties.
Intravaginal prasterone (Intrarosa) has a distinct safety profile dominated by application-site effects (vaginal discharge most commonly reported) rather than systemic androgenic effects, consistent with the intracrine local mechanism and the absence of clinically meaningful elevations in serum sex steroids 384347. The Intrarosa label warns against use in women with undiagnosed abnormal genital bleeding or with a history of, or active or suspected, breast cancer.
Hormone-sensitive cancer considerations: because DHEA is converted to estradiol and testosterone in peripheral tissues, it is contraindicated by most clinicians in patients with hormone-sensitive cancers (breast, prostate, endometrial) regardless of route. The FDA Intrarosa label includes this contraindication for the vaginal product 51. There are no high-quality long-term safety data on breast or prostate cancer outcomes with systemic DHEA in the general population; the Endocrine Society 2014 women's guideline notes this gap 40.
Other notable considerations: insomnia or mood activation has been reported at higher doses; lipid effects are modest and inconsistent (small reductions in HDL in some trials of women); insulin sensitivity effects are inconsistent 19. DHEA is a WADA-prohibited anabolic agent, athletes subject to anti-doping testing should not use DHEA in any route or formulation. OTC supplement quality concerns documented by Parasrampuria 1998 9 are an additional safety consideration favoring compounded preparations or FDA-approved Intrarosa when clinically indicated.
Contraindications
DHEA is contraindicated in patients with known or suspected hormone-sensitive cancers, breast, endometrial, prostate, or other malignancies that may be stimulated by androgens or estrogens. The FDA Intrarosa label specifically contraindicates use in women with undiagnosed abnormal genital bleeding or with known, suspected, or history of breast cancer 5140.
Pregnancy and lactation: DHEA is contraindicated in pregnancy. Conversion to estrogens and androgens makes systemic DHEA inappropriate during pregnancy. The Intrarosa label states the product is not indicated for use in women of reproductive potential 40.
Caution in patients with active liver disease (hepatic sulfation is the primary pharmacokinetic determinant of DHEA-S levels), polycystic ovary syndrome (DHEA can worsen hyperandrogenism), and uncontrolled cardiovascular disease (estrogenic effects are theoretically a concern at higher systemic doses, though clinical-trial data do not show a cardiovascular signal at typical replacement doses) 40.
Athletes subject to WADA, NCAA, or sport-specific anti-doping testing should not use DHEA in any route or formulation, DHEA is a prohibited anabolic agent in- and out-of-competition 40.
Drug interactions
DHEA is metabolized via sulfation (SULT2A1), oxidation (3β-HSD, 17β-HSD), and aromatization (CYP19A1). Drug interactions through these pathways are clinically modest at typical replacement doses 51. Important pharmacologic considerations include the additive effects with concurrent androgen or estrogen therapy (testosterone, estradiol, progestins), combination use raises the risk of androgenization or estrogenization beyond what monotherapy would produce.
Carbamazepine, phenytoin, and other inducers of hepatic metabolism may lower DHEA and DHEA-S levels. Conversely, oral contraceptives and exogenous estrogens raise SHBG and may alter the free testosterone produced from DHEA conversion. Anastrozole and other aromatase inhibitors block peripheral aromatization, blunting the estrogenic arm of DHEA action and altering the androgen-to-estrogen ratio.
Glucocorticoids suppress adrenal DHEA-S production and can be expected to interact with DHEA replacement; in adrenal insufficiency, DHEA replacement is added to glucocorticoid replacement rather than substituted for it 1028.
Adverse events
Across the published systemic DHEA trials in women, the most common adverse events are androgenic: acne (10, 30% on 50 mg/day in 4-month to 12-month trials), oily skin, mild hirsutism, scalp hair thinning, and rarely deepening of the voice 101130. These are dose-dependent and reversible with dose reduction. Women at typical replacement doses of 10, 25 mg/day report fewer androgenic events than at the 50 mg/day commonly used in research protocols.
Estrogenic adverse events are uncommon at typical replacement doses but include breast tenderness, vaginal spotting (in postmenopausal women), and theoretical concerns about endometrial stimulation. Long-term endometrial safety data are limited.
Insomnia and mood activation have been reported at higher doses (>100 mg/day) and are characteristic of the morning-dosing regimen. Lipid effects are modest and inconsistent across trials; small reductions in HDL cholesterol have been reported in some women's studies.
Insulin sensitivity effects are inconsistent: Villareal 2004 19 reported improved insulin action over 6 months; Nair 2006 26 reported no change at 2 years; Dhatariya 2005 20 reported improved insulin sensitivity in hypoadrenal women specifically.
Intravaginal prasterone (Intrarosa) adverse events in the phase III program were predominantly application-site related; vaginal discharge was the most common event, occurring in approximately 6% of treated participants in the pivotal trials 3342. Discontinuation rates were low. Systemic adverse events were uncommon, consistent with the lack of clinically meaningful elevation in serum sex steroids 3843.
Long-term cancer outcome data on systemic DHEA are limited; this is the principal reason the Endocrine Society women's androgen-therapy guideline 40 does not recommend systemic DHEA outside of adrenal insufficiency despite the symptom-relief evidence base.
Monitoring
Monitoring DHEA Therapy
Baseline assessment: serum DHEA-S, total and free testosterone, SHBG, estradiol, lipid panel, hepatic function, and clinical androgenization survey 45. In women of menopausal age, mammographic screening and endometrial assessment per general menopause-care guidelines. Pregnancy status confirmed in patients of reproductive potential.
On therapy: serum DHEA-S targeted to young-adult sex-specific reference range; free testosterone monitored in women to detect supraphysiologic exposure; androgenization survey at each visit (acne, oily skin, hirsutism, voice changes, scalp hair) 4038. Lipid panel annually. Endometrial assessment if abnormal uterine bleeding develops in postmenopausal women 51.
Intravaginal Intrarosa does not require serum sex-steroid monitoring at the labeled dose, as serum levels remain in the postmenopausal range 404347. Application-site assessment is appropriate at each visit.
Special populations
DHEA in Special Populations
Pregnancy
DHEA is contraindicated in pregnancy. Conversion to androgens and estrogens makes systemic DHEA inappropriate during pregnancy 32. The Intrarosa label states the product is not indicated for use in women of reproductive potential 51. Patients using DHEA for IVF poor-responder pre-stimulation typically discontinue DHEA at or shortly after embryo transfer; protocols vary and should be specified by the prescribing reproductive endocrinologist.
Lactation
There are no published data on DHEA in human milk or on its effects on the breastfed infant. Use during lactation is not recommended 51.
Pediatric
DHEA is not indicated in children. The use of DHEA outside of replacement for documented adrenal insufficiency is not appropriate in pediatric populations, and the Endocrine Society guidance on premature adrenarche does not recommend DHEA suppression or replacement in the absence of specific endocrine pathology 45.
Geriatric
Most published systemic DHEA trials enrolled adults in the 60, 80 age range. The largest definitive trial in this population, Nair 2006 NEJM 26, found no benefit of DHEA (or low-dose testosterone in men) on body composition, performance, insulin sensitivity, or quality of life at 2 years. The DHEAge study 15 reported small skin and libido improvements in women over 70 but no muscle benefit. Corona 2013 meta-analysis 37 reported small effects in elderly men. Use in eugonadal older adults for aging-related symptoms is not supported by high-quality evidence; the Endocrine Society 2014 women's guideline 40 does not recommend systemic DHEA for menopausal symptoms outside of adrenal insufficiency. When prescribed in older adults, monitor for androgenic effects more carefully (acne, hirsutism, hair thinning are more visible) and consider the lower end of the dose range.
Renal impairment
DHEA pharmacokinetics are not strongly dependent on renal clearance; renal impairment does not typically require dose adjustment of compounded oral DHEA. The Intrarosa label does not recommend dose adjustment on the basis of renal function 5113.
Hepatic impairment
Hepatic sulfation by SULT2A1 is the primary metabolic determinant of circulating DHEA-S levels. Patients with significant hepatic impairment may have altered DHEA and DHEA-S kinetics; clinical PK studies in hepatic impairment are limited 13. The Intrarosa label does not recommend dose adjustment on the basis of hepatic function but advises caution in patients with active liver disease 51.
Evidence quality
DHEA Evidence Quality
Evidence for intravaginal prasterone (Intrarosa) is the strongest in the DHEA literature: multiple phase III randomized double-blind placebo-controlled trials 334246 demonstrated effects on co-primary endpoints (vaginal pH, parabasal and superficial cell percentages, most bothersome symptom of pain at sexual activity) at 12 weeks, with mechanistic PK and serum-endocrine data 384347 supporting local intracrine action without clinically meaningful systemic estrogen or androgen elevation 51. FDA approval followed in November 2016.
Evidence for systemic oral DHEA in adrenal insufficiency is moderate: consistent positive randomized signals from Arlt 1999 10, Hunt 2000 11, Gurnell 2008 28, and Dhatariya 2005 20, integrated by the Alkatib 2009 meta-analysis 2951. Effect sizes on quality-of-life endpoints are small but statistically robust. The Endocrine Society 2016 guideline 45 acknowledges this evidence but does not routinely recommend, citing variable response and the absence of long-term outcome data.
Evidence for systemic DHEA in eugonadal aging adults is largely null or modest: Nair 2006 NEJM 26, Percheron 2003 15 (DHEAge), and Corona 2013 meta-analysis 37 do not support DHEA replacement for body composition, physical performance, insulin sensitivity, or general aging endpoints 51. Modest signals exist for bone mineral density 242531 mediated by aromatization to estrogens, but effects are smaller than FDA-approved bone-density agents.
Evidence for IVF poor-responder pre-stimulation is low quality per the Cochrane review 44 integrating Wiser 2010 32 (positive on pregnancy rate, n=33), Yeung 2014 39 (null on primary endpoint, n=72), and other small trials 51. The Zhang 2020 network meta-analysis 48 places DHEA in the context of broader adjuvant strategies. Practice adoption exceeds the evidence base; patient counseling should reflect this.
Evidence for SLE is insufficient. Two Petri-led phase III trials 1617 reported modest signals but did not produce an FDA-approved indication; the prasterone development program (GL-701) was discontinued 51.
Evidence for mood and depression is limited but includes one positive monotherapy RCT in midlife-onset depression 21 and earlier signals 2251. Use for psychiatric indications is investigational.
Critically, evidence for compounded DHEA specifically does not exist as a separate program, compounded preparations rely on the manufactured (Intrarosa) and supplement-derived (oral systemic) PK and clinical evidence base, with the caveat that compounded preparations may differ in concentration, excipient profile, and route 51. The Parasrampuria 1998 JAMA quality study 9 documents the gap that compounded preparations under USP <795> 54 are positioned to address relative to the unregulated OTC supplement market.
Randomized double-blind placebo-controlled crossover trial of oral DHEA 50 mg/day in women with adrenal insufficiency
24
4 months per arm
Improved mood, fatigue, sexuality, and overall well-being scores vs placebo; landmark trial establishing DHEA replacement as a clinical option in adrenal insufficiency 10
Randomized double-blind placebo-controlled trial of DHEA 75 mg/day in men and 50 mg/day in women (plus low-dose testosterone arm in men)
144
2 years
No benefit of DHEA on body composition, physical performance, insulin sensitivity, or quality of life, definitive negative trial in eugonadal aging adults 26
Phase III randomized double-blind placebo-controlled trial of intravaginal prasterone (DHEA) in postmenopausal women with vulvovaginal atrophy
—
12 weeks
Significant improvement in vaginal pH, percentage of parabasal and superficial cells, and pain at sexual activity vs placebo, pivotal evidence for Intrarosa approval pathway 33
Phase III randomized double-blind placebo-controlled trial of intravaginal prasterone 6.5 mg daily in postmenopausal women with moderate-to-severe dyspareunia
—
12 weeks
Significant improvement in co-primary endpoints (vaginal pH, parabasal cells, superficial cells, pain at sexual activity); supported FDA approval of Intrarosa in 2016 42
PK study of oral DHEA after dexamethasone suppression in young healthy women
—
—
Characterized peripheral conversion to androstenedione, testosterone, and estrogens; established the dose-response relationship for compounded oral dosing 8
Independent assay of commercial OTC DHEA dietary-supplement products
—
—
Substantial variability between labeled and assayed DHEA content; demonstrates a quality gap in the OTC supplement market that compounded preparations under USP <795> can address 9
Cross-sectional measurement of serum DHEA-S across adulthood
—
—
Established the age-related decline of DHEA-S, the adrenopause trajectory 1
Mechanism detail
Detailed Mechanism of DHEA
Adrenal biosynthesis. DHEA is synthesized in the zona reticularis from pregnenolone by the 17,20-lyase activity of CYP17A1, with the cofactor cytochrome b5 enhancing lyase versus hydroxylase activity. The reticularis is unique in its high b5 expression and low 3β-HSD activity, which channels precursors toward DHEA rather than into the glucocorticoid or mineralocorticoid pathways. DHEA is sulfated by SULT2A1 to DHEA-S; the sulfate ester is the predominant circulating form and has a much longer half-life (hours to a day) than free DHEA (minutes to ~1 hour). Steroid sulfatase (STS) regenerates free DHEA from DHEA-S at peripheral tissues for local conversion 45.
Intracrine conversion. Labrie's intracrinology framework 3 holds that, after the adolescent gonadal surge wanes (in women, after menopause; in older men, as testicular output declines), peripheral tissues meet their sex-steroid needs by local conversion of circulating DHEA and DHEA-S. The vaginal epithelium expresses STS, 3β-HSD, 17β-HSD, and aromatase, producing local estradiol and testosterone from intravaginal DHEA without raising systemic concentrations beyond the postmenopausal range, the mechanistic basis for Intrarosa 384743. Bone, brain, adipose, and skin show comparable but tissue-specific enzyme repertoires.
Adrenarche and adrenopause. The lifespan trajectory of DHEA-S is well characterized. Orentreich's cross-sectional 1 and longitudinal 2 studies in J Clin Endocrinol Metab quantified the rise of DHEA-S at adrenarche (ages 6, 8), its peak in the third decade, and its decline at approximately 1, 2% per year thereafter. By the seventh and eighth decades, serum DHEA-S is 10, 20% of young-adult values, an order-of-magnitude decline that distinguishes adrenopause from the comparatively modest fall in testosterone with age. The biological significance of this decline is contested: it correlates with multiple aspects of aging biology but causality is not established, and DHEA replacement trials in eugonadal older adults have been largely null on hard endpoints 2637.
Pharmacokinetics of oral and intravaginal DHEA. Oral DHEA undergoes first-pass sulfation to DHEA-S and rapidly raises serum DHEA-S; in young women given dexamethasone-suppressed baseline, single-dose oral DHEA produced predictable serum DHEA, DHEA-S, androstenedione, testosterone, and estradiol elevations dose-proportionally 8. In healthy elderly subjects, daily oral DHEA 50 mg produced steady-state DHEA-S elevations within the young-adult reference range and a smaller increase in testosterone (more pronounced in women than men) 13. Long-term daily oral DHEA in young men was characterized by Acacio 2004 23. Intravaginal prasterone produces tissue-level local action with serum DHEA, DHEA-S, testosterone, and estradiol concentrations remaining within postmenopausal reference ranges 384743. Sublingual and topical compounded routes have less published PK data and produce concentration profiles that depend strongly on excipient formulation.
Neurosteroid actions. DHEA and DHEA-S act at low affinity on GABA-A receptors (where DHEA-S is a negative allosteric modulator, contrasting with positive allosteric modulation by allopregnanolone), NMDA receptors, and the sigma-1 receptor 14. These actions are pharmacologically distinct from androgen/estrogen-receptor-mediated effects and have been hypothesized to underlie reported mood and cognitive effects, though the clinical-trial signal for systemic DHEA on mood and cognition in healthy older adults is weak to absent.
WADA / doping. The World Anti-Doping Agency lists DHEA as a prohibited anabolic agent under section S1.1b of the Prohibited List, both in- and out-of-competition. Oral DHEA reliably raises urinary testosterone and androsterone glucuronide metabolites and can produce positive testosterone:epitestosterone ratios and IRMS abnormalities used in anti-doping testing. Compounded DHEA preparations for individual clinical use are not exempted from sport-specific bans.
Pharmacology
DHEA Pharmacokinetics & Pharmacodynamics
Pharmacokinetics
Oral DHEA undergoes rapid hepatic and intestinal sulfation by SULT2A1 to DHEA-S, which is the predominant circulating form (half-life ~7, 10 hours). Free DHEA has a much shorter half-life (~1 hour). After dexamethasone suppression of endogenous adrenal production, single-dose oral DHEA 50 mg in young women produced serum DHEA, DHEA-S, androstenedione, testosterone, and estradiol rises dose-proportionally 8. Daily oral DHEA 50 mg in healthy elderly subjects restored DHEA-S to young-adult reference values, with smaller increases in testosterone (more pronounced in women than men) 13. Long-term daily oral DHEA in young men produced steady-state DHEA-S elevations with concurrent androstenedione and testosterone rises 23.
Intravaginal prasterone (Intrarosa 6.5 mg daily) produced local tissue action, restored vaginal pH and cell maturation, without clinically significant elevation of serum DHEA, DHEA-S, testosterone, or estradiol beyond the postmenopausal reference range 384347. This PK profile is the mechanistic basis for the FDA approval of Intrarosa and distinguishes intravaginal from oral systemic dosing.
Compounded sublingual and topical preparations have less published PK data. Sublingual delivery is hypothesized to partially bypass first-pass sulfation, producing a higher DHEA-to-DHEA-S ratio than oral capsules, but published PK studies are limited and excipient-dependent. Compounded preparations are not bioequivalent to OTC supplement products or to Intrarosa.
Pharmacodynamics
DHEA functions predominantly as an intracrine substrate 10. Pharmacodynamic effects depend on tissue-specific expression of steroid sulfatase, 3β-HSD, 17β-HSD, aromatase, and 5α-reductase, each tissue converts circulating DHEA and DHEA-S to the active androgen or estrogen profile appropriate to that tissue 338.
Measured clinical effects in randomized trials include: serum DHEA-S elevation to young-adult ranges; modest testosterone rise (greater in women than men); small estradiol rise; vaginal pH normalization and cell maturation index improvement with intravaginal dosing; improved mood, fatigue, and well-being scores in adrenal insufficiency; modest bone-density gains in older adults mediated by aromatization to estrogens; and dose-dependent androgenization (acne, oily skin, hirsutism) particularly in women 1025.
Effects on body composition, physical performance, cognition, and metabolic endpoints in eugonadal aging adults are largely null or modest 26153725.
Comparative formulations
Comparing DHEA Formulations
The FDA-approved Intrarosa vaginal insert (6.5 mg prasterone) is the only DHEA product with FDA pre-market efficacy and quality review 3851. It is the appropriate choice for postmenopausal dyspareunia from vulvovaginal atrophy. Serum sex-steroid levels remain in the postmenopausal range during use 43.
OTC oral DHEA capsules (commonly 25, 50, or 100 mg) are sold as dietary supplements without FDA pre-market quality or efficacy review. Independent assays have shown substantial variability between labeled and assayed content 9. For patients in whom OTC supplements are clinically appropriate, the lowest commercially available dose is typically 25 mg, which exceeds the 10, 25 mg dose appropriate for many women.
Compounded oral DHEA capsules and sublingual troches under USP <795> 54 address dose individualization (5, 10, 15, 20 mg increments not commercially available), excipient sensitivity, and identity/potency assurance, areas where the OTC supplement market has documented variability 947. Compounded topical DHEA is used in selected patients but has minimal published PK characterization.
Compounded preparations are not bioequivalent to Intrarosa and are not bioequivalent to any specific OTC product. Switching between routes should be accompanied by reassessment of DHEA-S and clinical response 43.
Storage
DHEA Storage and Handling
Intrarosa is stored at controlled room temperature (20, 25°C; 68, 77°F) with excursions permitted between 15, 30°C (59, 86°F) per the FDA label 5154. Inserts are individually packaged and used with the supplied applicator.
Compounded oral DHEA capsules and sublingual troches are stored at controlled room temperature per the pharmacy's stability and beyond-use date assignment under USP <795>. DHEA active pharmaceutical ingredient is light-sensitive; compounded preparations are typically dispensed in amber or opaque containers 54.
RonanRx operations
DHEA Compounding & Operations
503A compounding
Compounded DHEA is prepared under 503A on patient-specific prescriptions in state-licensed compounding pharmacies. RonanRx prepares nonsterile DHEA preparations (oral capsules, sublingual troches, topical creams) per USP General Chapter <795>, the official compendial standard for nonsterile pharmaceutical compounding 5453. Documented active ingredient sourcing, gravimetric and analytical verification, identity testing (e.g., HPLC or USP-monograph methods), and lot traceability are standard.
Beyond-use dating, ingredient identity verification, and stability assessment follow USP <795> requirements 53. Each compounded batch is documented per state board of pharmacy retention rules with full traceability from API lot through dispensing. The Parasrampuria 1998 JAMA study 9 documenting variability in OTC supplement DHEA content is one of the principal historical references motivating USP-compliant compounded preparations as a quality-assurance alternative when patient-specific clinical need is documented.
Pharmacist review
Each prescription for compounded DHEA undergoes pharmacist review prior to dispensing. The review confirms: a documented patient-specific clinical reason that the OTC supplement market or FDA-approved Intrarosa product cannot meet the patient's clinical need (sub-OTC dose, sublingual/topical formulation, excipient sensitivity, or USP <795> identity/potency assurance); absence of contraindications (hormone-sensitive cancer, undiagnosed abnormal genital bleeding, pregnancy, lactation); appropriate concomitant medication review (concurrent androgen, estrogen, or aromatase inhibitor therapy); and a prescribed regimen consistent with the published trial dosing in the relevant indication 51.
RonanRx is particularly attentive to the FDA 'essentially-a-copy' framework for oral DHEA 52, even though there is no FDA-approved oral DHEA comparator, the existence of an OTC supplement market raises analogous questions, and prescriptions are reviewed for clinical rationale that an OTC product cannot satisfy 9. For postmenopausal dyspareunia, the Intrarosa product is the appropriate first-line choice; compounded intravaginal DHEA is reserved for documented patient-specific reasons (excipient sensitivity, dose individualization) 5154.
Quality and traceability
Active pharmaceutical ingredients are sourced from FDA-registered facilities with documented certificates of analysis (CoA) including identity, assay, residual solvents, and heavy-metals testing. Each batch is recorded with lot numbers traceable to API source, compounding date, beyond-use date, identity verification (HPLC or USP-monograph method), and dispensing pharmacist of record 54. Finished product lot records are retained per state board of pharmacy retention requirements. The supplement-market quality gap documented by Parasrampuria 1998 9 is one of the principal motivations for the USP <795>-compliant traceability standard applied to compounded DHEA.
FAQ
Frequently Asked Questions About DHEA
Is DHEA the same as testosterone or estrogen?
No. DHEA is a precursor that the body converts to small amounts of testosterone and estrogen inside specific tissues. It is not testosterone or estrogen itself, and its effects depend on each tissue's enzymes for converting it, a process called intracrinology 3.
Why is oral DHEA available over the counter?
DHEA is sold OTC as a dietary supplement in the US under the Dietary Supplement Health and Education Act of 1994. This is unusual for a sex-steroid prohormone, and it means OTC products are not subject to FDA pre-market quality or efficacy review 9. Independent analyses have documented substantial variability between labeled and actual DHEA content in commercial supplements.
What is Intrarosa?
Intrarosa is the only FDA-approved DHEA product, a 6.5 mg prasterone vaginal insert approved in November 2016 for moderate-to-severe painful intercourse in postmenopausal women caused by vulvovaginal atrophy 51. The pivotal trials (Labrie 2011, Archer 2015) showed improvement in vaginal pH, cell maturation, and pain without clinically significant elevation of serum estrogens or androgens 3342.
When is a compounded DHEA preparation appropriate?
Per FDA 503A standards, compounded preparations are appropriate when the prescriber documents a patient-specific clinical need that neither the OTC supplement market nor the FDA-approved Intrarosa product can meet 52954. Common reasons: sub-OTC doses (10, 25 mg, common for women); sublingual or topical formulation; excipient sensitivity to OTC product fillers; or USP <795>-compliant identity and potency. Cost or preference alone does not qualify.
Does DHEA work for anti-aging?
Evidence in healthy older adults is largely null. The definitive Mayo Clinic trial (Nair 2006, NEJM) of 87 men and 57 women aged 60, 88 on DHEA for 2 years found no benefit on body composition, physical performance, insulin sensitivity, or quality of life 26. The earlier DHEAge study (Percheron 2003) reported small skin and libido improvements in women over 70 but no muscle benefit 15. Compounding pharmacies should not market DHEA for anti-aging.
Does DHEA help with adrenal insufficiency?
Yes, this is the strongest off-label use case. Multiple randomized trials (Arlt 1999 NEJM; Hunt 2000; Gurnell 2008) and a meta-analysis (Alkatib 2009) show that DHEA 25, 50 mg/day improves mood, fatigue, and well-being scores in women with adrenal insufficiency who remain symptomatic on optimal glucocorticoid and mineralocorticoid replacement 101128. The Endocrine Society 2016 guideline permits but does not routinely recommend 4529.
Does DHEA help with IVF?
It is widely used in poor-responder IVF protocols (75 mg/day for 6, 12 weeks pre-stimulation), but the supporting evidence is low quality. The Cochrane 2015 review found that androgen pre-treatment 'may improve live birth rate' but high-quality data are lacking. The Wiser 2010 trial was positive (n=33); the Yeung 2014 pilot was null on the primary endpoint (n=72) 3239. Patients should be counseled that benefit is plausible but unproven 44.
What are the most common side effects?
Androgenic effects in women, acne, oily skin, mild hirsutism, scalp hair thinning, are the most common and are dose-dependent. They occur in 10, 30% of women on 50 mg/day in research protocols and are typically reversible with dose reduction 1030. Estrogenic effects (breast tenderness, vaginal spotting) are less common. Intravaginal Intrarosa has a distinct profile dominated by application-site events (vaginal discharge) rather than systemic effects 33.
Who should not take DHEA?
Patients with known or suspected hormone-sensitive cancers (breast, endometrial, prostate), undiagnosed abnormal genital bleeding, pregnancy, lactation, or active liver disease. Competitive athletes subject to WADA, NCAA, or other anti-doping testing should not use DHEA, it is a prohibited anabolic agent in- and out-of-competition 5140.
Does RonanRx sell DHEA directly to patients?
No. Compounded DHEA requires a patient-specific prescription written by a licensed prescriber for an identified patient with a documented clinical reason that OTC supplements or the FDA-approved Intrarosa product cannot meet the patient's need, plus pharmacist review before dispensing 52. RonanRx is not a direct-to-consumer storefront 53.
Clinician resource
Download the DHEA Clinical Monograph (PDF)
The full white paper covers every section on this page plus chemical identity, evidence grading, indication-by-indication summaries, research gaps, and reference appendix. Suitable for sharing with prescribing doctors and pharmacist reviewers.
[orentreich1984] Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. Journal of Clinical Endocrinology & Metabolism. 1984. PMID 6235241. (accessed 2026-05-11)
[orentreich1992] Orentreich N, Brind JL, Vogelman JH, Andres R, Baldwin H. Long-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men. Journal of Clinical Endocrinology & Metabolism. 1992. PMID 1400863. (accessed 2026-05-11)
[labrie1991intracrinology] Labrie F. Intracrinology. Molecular and Cellular Endocrinology. 1991. PMID 1838082. (accessed 2026-05-11)
[miller2011steroidogenesis] Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocrine Reviews. 2011. PMID 21051590. (accessed 2026-05-11)
[miller2012lyase] Miller WL. The syndrome of 17,20 lyase deficiency. Journal of Clinical Endocrinology & Metabolism. 2012. PMID 22072737. (accessed 2026-05-11)
[havelock2004adrenarche] Havelock JC, Auchus RJ, Rainey WE. The rise in adrenal androgen biosynthesis: adrenarche. Seminars in Reproductive Medicine. 2004. PMID 15635501. (accessed 2026-05-11)
[morales1994] Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. Journal of Clinical Endocrinology & Metabolism. 1994. PMID 7515387. (accessed 2026-05-11)
[arlt1998pk] Arlt W, Justl HG, Callies F, Reincke M, Hübler D, Oettel M, Ernst M, Schulte HM, Allolio B. Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. Journal of Clinical Endocrinology & Metabolism. 1998. PMID 9626121. (accessed 2026-05-11)
[parasrampuria1998] Parasrampuria J, Schwartz K, Petesch R. Quality control of dehydroepiandrosterone dietary supplement products. JAMA. 1998. PMID 9820251. (accessed 2026-05-11)
[arlt1999nejm] Arlt W, Callies F, van Vlijmen JC, Koehler I, Reincke M, Bidlingmaier M, Huebler D, Oettel M, Ernst M, Schulte HM, Allolio B. Dehydroepiandrosterone replacement in women with adrenal insufficiency. New England Journal of Medicine. 1999. PMID 10502590. (accessed 2026-05-11)
[hunt2000] Hunt PJ, Gurnell EM, Huppert FA, Richards C, Prevost AT, Wass JA, Herbert J, Chatterjee VK. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. Journal of Clinical Endocrinology & Metabolism. 2000. PMID 11134123. (accessed 2026-05-11)
[callies2001women] Callies F, Fassnacht M, van Vlijmen JC, Koehler I, Huebler D, Seibel MJ, Arlt W, Allolio B. Dehydroepiandrosterone replacement in women with adrenal insufficiency: effects on body composition, serum leptin, bone turnover, and exercise capacity. Journal of Clinical Endocrinology & Metabolism. 2001. PMID 11344193. (accessed 2026-05-11)
[legrain2000pk] Legrain S, Massien C, Lahlou N, Roger M, Debuire B, Diquet B, Chatellier G, Azizi M, Faucounau V, Porchet H, Forette F, Baulieu EE. Dehydroepiandrosterone replacement administration: pharmacokinetic and pharmacodynamic studies in healthy elderly subjects. Journal of Clinical Endocrinology & Metabolism. 2000. PMID 10999810. (accessed 2026-05-11)
[baulieu2000dheage] Baulieu EE, Thomas G, Legrain S, Lahlou N, Roger M, Debuire B, Faucounau V, Girard L, Hervy MP, Latour F, Leaud MC, Mokrane A, Pitti-Ferrandi H, Trivalle C, de Lacharrière O, Nouveau S, Rakoto-Arison B, Souberbielle JC, Raison J, Le Bouc Y, Raynaud A, Girerd X, Forette F. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proceedings of the National Academy of Sciences USA. 2000. PMID 10760294. (accessed 2026-05-11)
[percheron2003] Percheron G, Hogrel JY, Denot-Ledunois S, Fayet G, Forette F, Baulieu EE, Fardeau M, Marini JF; Double-blind placebo-controlled trial. Effect of 1-year oral administration of dehydroepiandrosterone to 60- to 80-year-old individuals on muscle function and cross-sectional area: a double-blind placebo-controlled trial. Archives of Internal Medicine. 2003. PMID 12639206. (accessed 2026-05-11)
[petri2002sle] Petri MA, Lahita RG, Van Vollenhoven RF, Merrill JT, Schiff M, Ginzler EM, Strand V, Kunz A, Gorelick KJ, Schwartz KE. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis & Rheumatism. 2002. PMID 12124866. (accessed 2026-05-11)
[petri2004sleactive] Petri MA, Mease PJ, Merrill JT, Lahita RG, Iannini MJ, Yocum DE, Ginzler EM, Katz RS, Gluck OS, Genovese MC, Van Vollenhoven R, Kalunian KC, Manzi S, Greenwald MW, Buyon JP, Olsen NJ, Schiff MH, Kavanaugh AF, Caldwell JR, Ramsey-Goldman R, St Clair EW, Goldman AL, Egan RM, Polisson RP, Moder KG, Rothfield NF, Spencer RT, Hobbs K, Fessler BJ, Calabrese LH, Moreland LW, Cohen SB, Quarles BJ, Strand V, Gurwith M, Schwartz KE. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis & Rheumatism. 2004. PMID 15452837. (accessed 2026-05-11)
[verthelyi2001sle] Verthelyi D, Petri M, Ylamus M, Klinman DM. Disassociation of sex hormone levels and cytokine production in SLE patients. Lupus. 2001. PMID 11403266. (accessed 2026-05-11)
[villareal2004] Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. JAMA. 2004. PMID 15536111. (accessed 2026-05-11)
[dhatariya2005] Dhatariya K, Bigelow ML, Nair KS. Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabetes. 2005. PMID 15734854. (accessed 2026-05-11)
[schmidt2005depression] Schmidt PJ, Daly RC, Bloch M, Smith MJ, Danaceau MA, St Clair LS, Murphy JH, Haq N, Rubinow DR. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Archives of General Psychiatry. 2005. PMID 15699292. (accessed 2026-05-11)
[wolkowitz1997depression] Wolkowitz OM, Reus VI, Roberts E, Manfredi F, Chan T, Raum WJ, Ormiston S, Johnson R, Canick J, Brizendine L, Weingartner H. Dehydroepiandrosterone (DHEA) treatment of depression. Biological Psychiatry. 1997. PMID 9024954. (accessed 2026-05-11)
[acacio2004pk] Acacio BD, Stanczyk FZ, Mullin P, Saadat P, Jafarian N, Sokol RZ. Pharmacokinetics of dehydroepiandrosterone and its metabolites after long-term daily oral administration to healthy young men. Fertility and Sterility. 2004. PMID 15037408. (accessed 2026-05-11)
[jankowski2006bone] Jankowski CM, Gozansky WS, Schwartz RS, Dahl DJ, Kittelson JM, Scott SM, Van Pelt RE, Kohrt WM. Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: a randomized, controlled trial. Journal of Clinical Endocrinology & Metabolism. 2006. PMID 16735495. (accessed 2026-05-11)
[jankowski2008estrogen] Jankowski CM, Gozansky WS, Van Pelt RE, Schenkman ML, Wolfe P, Schwartz RS, Kohrt WM. Increases in bone mineral density in response to oral dehydroepiandrosterone replacement in older adults appear to be mediated by serum estrogens. Journal of Clinical Endocrinology & Metabolism. 2008. PMID 18812486. (accessed 2026-05-11)
[nair2006nejm] Nair KS, Rizza RA, O'Brien P, Dhatariya K, Short KR, Nehra A, Vittone JL, Klee GG, Basu A, Basu R, Cobelli C, Toffolo G, Dalla Man C, Tindall DJ, Melton LJ 3rd, Smith GE, Khosla S, Jensen MD. DHEA in elderly women and DHEA or testosterone in elderly men. New England Journal of Medicine. 2006. PMID 17050889. (accessed 2026-05-11)
[gurnell2008longterm] Gurnell EM, Hunt PJ, Curran SE, Conway CL, Pullenayegum EM, Huppert FA, Compston JE, Herbert J, Chatterjee VK. Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. Journal of Clinical Endocrinology & Metabolism. 2008. PMID 18000094. (accessed 2026-05-11)
[alkatib2009meta] Alkatib AA, Cosma M, Elamin MB, Erickson D, Swiglo BA, Erwin PJ, Montori VM. A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency. Journal of Clinical Endocrinology & Metabolism. 2009. PMID 19773400. (accessed 2026-05-11)
[panjari2009sexual] Panjari M, Bell RJ, Jane F, Adams J, Morrow C, Davis SR. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. Journal of Sexual Medicine. 2009. PMID 19619146. (accessed 2026-05-11)
[weiss2009bone] Weiss EP, Villareal DT, Fontana L, Han DH, Holloszy JO. Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone. American Journal of Clinical Nutrition. 2009. PMID 19321570. (accessed 2026-05-11)
[wiser2010ivf] Wiser A, Gonen O, Ghetler Y, Shavit T, Berkovitz A, Shulman A. Addition of dehydroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study. Human Reproduction. 2010. PMID 20729538. (accessed 2026-05-11)
[labrie2011dyspareunia] Labrie F, Archer DF, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric. 2011. PMID 21244215. (accessed 2026-05-11)
[davis2011review] Davis SR, Panjari M, Stanczyk FZ. Clinical review: DHEA replacement for postmenopausal women. Journal of Clinical Endocrinology & Metabolism. 2011. PMID 21411558. (accessed 2026-05-11)
[genazzani2011climacteric] Genazzani AR, Stomati M, Valentino V, Pluchino N, Pot E, Casarosa E, Merlini S, Giannini A, Luisi M. Effect of 1-year, low-dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric. 2011. PMID 21942655. (accessed 2026-05-11)
[genazzani2003neuroactive] Genazzani AD, Stomati M, Bernardi F, Pieri M, Rovati L, Genazzani AR. Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids. Fertility and Sterility. 2003. PMID 14667889. (accessed 2026-05-11)
[corona2013meta] Corona G, Rastrelli G, Giagulli VA, Sila A, Sforza A, Forti G, Mannucci E, Maggi M. Dehydroepiandrosterone supplementation in elderly men: a meta-analysis study of placebo-controlled trials. Journal of Clinical Endocrinology & Metabolism. 2013. PMID 23824417. (accessed 2026-05-11)
[labrie2013local] Labrie F, Martel C, Bélanger A, Pelletier G. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens. Journal of Steroid Biochemistry and Molecular Biology. 2013. PMID 23954500. (accessed 2026-05-11)
[yeung2014ivf] Yeung TW, Chai J, Li RH, Lee VC, Ho PC, Ng EH. A randomized, controlled, pilot trial on the effect of dehydroepiandrosterone on ovarian response markers, ovarian response, and in vitro fertilization outcomes in poor responders. Fertility and Sterility. 2014. PMID 24796766. (accessed 2026-05-11)
[wierman2014women] Wierman ME, Arlt W, Basson R, Davis SR, Miller KK, Murad MH, Rosner W, Santoro N. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2014. PMID 25279570. (accessed 2026-05-11)
[scheffers2015cochrane] Scheffers CS, Armstrong S, Cantineau AE, Farquhar C, Jordan V. Dehydroepiandrosterone for women in the peri- or postmenopausal phase. Cochrane Database of Systematic Reviews. 2015. PMID 25879093. (accessed 2026-05-11)
[archer2015dyspareunia] Archer DF, Labrie F, Bouchard C, Portman DJ, Koltun W, Cusan L, Labrie C, Côté I, Lavoie L, Martel C, Balser J; VVA Prasterone Group. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause. 2015. PMID 25734980. (accessed 2026-05-11)
[ke2015serum] Ke Y, Labrie F, Gonthier R, Simard JN, Bergeron D, Martel C, Vaillancourt M, Montesino M, Lavoie L, Archer DF, Balser J, Moyneur É; Members of the Prasterone Clinical Research Group. Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration. Journal of Steroid Biochemistry and Molecular Biology. 2015. PMID 26291918. (accessed 2026-05-11)
[nagels2015cochrane] Nagels HE, Rishworth JR, Siristatidis CS, Kroon B. Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction. Cochrane Database of Systematic Reviews. 2015. PMID 26608695. (accessed 2026-05-11)
[bornstein2016endo] Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, Husebye ES, Merke DP, Murad MH, Stratakis CA, Torpy DJ. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2016. PMID 26760044. (accessed 2026-05-11)
[labrie2017menocombined] Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur É; VVA Prasterone Research Group. Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause. Menopause. 2017. PMID 28640161. (accessed 2026-05-11)
[labrie2017lowdose] Labrie F, Martel C. A low dose (6.5 mg) of intravaginal DHEA permits a strictly local action while maintaining all serum estrogens or androgens as well as their metabolites within normal values. Hormone Molecular Biology and Clinical Investigation. 2017. PMID 27997350. (accessed 2026-05-11)
[zhang2020nma] Zhang Y, Zhang C, Shu J, Guo J, Chang HM, Leung PCK, Sheng JZ, Huang H. Adjuvant treatment strategies in ovarian stimulation for poor responders undergoing IVF: a systematic review and network meta-analysis. Human Reproduction Update. 2020. PMID 32045470. (accessed 2026-05-11)
[rabijewski2020] Rabijewski M, Papierska L, Binkowska M, Maksym R, Jankowska K, Skrzypulec-Plinta V, Zgliczynski W. Supplementation of dehydroepiandrosterone (DHEA) in pre- and postmenopausal women - position statement of expert panel of Polish Menopause and Andropause Society. Ginekologia Polska. 2020. PMID 33030737. (accessed 2026-05-11)
[burger2002androgen] Burger HG. Androgen production in women. Fertility and Sterility. 2002. PMID 12007895. (accessed 2026-05-11)
[fda_essentially_a_copy] U.S. Food and Drug Administration. Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act — Guidance for Industry. FDA Guidance for Industry. 2018. https://www.fda.gov/media/98973/download (accessed 2026-05-11)
[usp_795] United States Pharmacopeia. USP General Chapter <795> Pharmaceutical Compounding — Nonsterile Preparations. USP Compounding Compendium. 2023. https://www.usp.org/compounding/general-chapter-795 (accessed 2026-05-11)
How to access
How to Access DHEA
Compounded DHEA is dispensed under 503A on a patient-specific prescription. Pick the path that matches where you're starting from.
For doctors
Offer this medication.
A pharmacist will follow up within two business days. We'll cover state availability, supported formulations, and what integration looks like for your clinic.
If your doctor has already prescribed DHEA, sign up so we can prepare and ship your medication. The signup wizard collects intake and connects you to the prescribing workflow.
RonanRx prescribes through partner clinics — we don't initiate prescriptions on this site. See how the referral works and how to find a clinic in your state that has evaluated patients for DHEA.
